Market Overview:
The global kidney/renal fibrosis treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as increasing incidence of renal fibrosis, rising awareness about available treatments, and technological advancements in the field of renal fibrosis treatment. The global kidney/renal fibrosis treatment market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into angiotensin II receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors, pirfenidone, renin inhibitors, and vasopeptidase inhibitors. On the basis of application, the market is segmented into commercial/private hospitals; public health hospitals; clinics; and home treatment. The regional segments are North America; Latin America; Europe; Asia Pacific ;and Middle East & Africa .
Product Definition:
Kidney/Renal Fibrosis Treatment is a medical procedure that is used to help treat kidney or renal fibrosis. This treatment can help improve the function of the kidneys and may also help to slow down the progression of the disease.
Angiotensin II Receptor Blockers (ARBs):
The ARBs are the group of drugs that works by relaxing the muscles of bladder and urinary tract. The angiotensin II is a chemical messenger that is produced in the kidney when it does not function properly. Angiotensin II acts on receptors present on cells in the urinary tract and bladder to cause urine retention, increased frequency of urination, and decreased urine volume.
Angiotensin Converting Enzyme (ACE) Inhibitors:
The global angiotensin converting enzyme (ACE) inhibitors and it's usage in kidney/renal fibrosis treatment market size was valued at USD 2.4 billion in 2015 and is expected to grow at a CAGR of XX% over the forecast period. The growing prevalence of chronic kidney diseases, especially diabetes-related renal disorders is one of the major factors anticipated to boost growth during the forecast period.
Application Insights:
The public health hospitals segment dominated the market for kidney/renal fibrosis treatment and held the largest share of 34.1% in 2017. This is owing to the availability of less expensive drugs for treating kidney/renal fibrosis at public health hospitals compared to commercial or private hospitals. Moreover, a rise in prevalence of chronic diseases such as hypertension, diabetes mellitus and heart diseases increases demand for renal care services at public healthcare facilities thus leading to increased revenue generation opportunities for pharmaceutical companies manufacturing angiotensin II receptor blockers (ARBs), ACE inhibitors and pirfenidone, among others.
Commercial/private hospitals are anticipated to be one of the fastest-growing segments over the forecast period due largely their ability to provide advanced treatment options with higher cure rates than that offered by clinics or other hospital units offering similar services across various regions globally.
Regional Analysis:
North America dominated the global kidney/renal fibrosis treatment market in 2017. High adoption of innovative products and high healthcare expenditure are some factors responsible for its large share. Moreover, the presence of key players in this region is also expected to contribute towards its large revenue share over the forecast period.
Asia Pacific is anticipated to grow at a lucrative rate during the forecast period owing to increasing government initiatives and awareness programs regarding chronic diseases such as kidney & renal fibrosis being conducted by various organizations such as WHO, Pritish Nair-Sharma Memorial Foundation (PSMFMF), Indian Council of Medical Research (ICMR) etc., which will drive growth in this region. In addition, growing medical tourism industry due to availability of advanced treatments at cheaper costs will further propel growth during the forecast period.
Growth Factors:
- Increasing incidence of kidney diseases and renal fibrosis
- Growing awareness about the available treatment options for kidney diseases and renal fibrosis
- Rising demand for better and more effective treatments for kidney diseases and renal fibrosis
- Technological advancements in the field of kidney disease treatment that offer improved outcomes to patients with renal fibrosis
- Availability of government funding and support for research on new treatments for kidney diseases and renal fibrosis
Scope Of The Report
Report Attributes
Report Details
Report Title
Kidney/Renal Fibrosis Treatment Market Research Report
By Type
Angiotensin II Receptor Blockers (ARBs), Angiotensin Converting Enzyme (ACE) Inhibitors, Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors
By Application
Commercial/Private Hospitals, Public Health Hospitals, Clinics, Home Treatment
By Companies
Galectin Therapeutics, Merck & Co., F. Hoffman-La Roche Ltd., Pfizer Inc., InterMune Inc., ProMetic Life-Sciences Inc., La Jolla Pharmaceutical Company, Genzyme Corporation, BioLine Rx Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
170
Number of Tables & Figures
119
Customization Available
Yes, the report can be customized as per your need.
Global Kidney/Renal Fibrosis Treatment Market Report Segments:
The global Kidney/Renal Fibrosis Treatment market is segmented on the basis of:
Types
Angiotensin II Receptor Blockers (ARBs), Angiotensin Converting Enzyme (ACE) Inhibitors, Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Commercial/Private Hospitals, Public Health Hospitals, Clinics, Home Treatment
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Galectin Therapeutics
- Merck & Co.
- F. Hoffman-La Roche Ltd.
- Pfizer Inc.
- InterMune Inc.
- ProMetic Life-Sciences Inc.
- La Jolla Pharmaceutical Company
- Genzyme Corporation
- BioLine Rx Ltd
Highlights of The Kidney/Renal Fibrosis Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Angiotensin II Receptor Blockers (ARBs)
- Angiotensin Converting Enzyme (ACE) Inhibitors
- Pirfenidone
- Renin Inhibitors
- Vasopeptidase Inhibitors
- By Application:
- Commercial/Private Hospitals
- Public Health Hospitals
- Clinics
- Home Treatment
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Kidney/Renal Fibrosis Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Kidney/Renal Fibrosis Treatment is a treatment for kidney and renal fibrosis. It helps to improve the function of the kidneys and reduce the risk of kidney failure.
Some of the major companies in the kidney/renal fibrosis treatment market are Galectin Therapeutics, Merck & Co., F. Hoffman-La Roche Ltd., Pfizer Inc., InterMune Inc., ProMetic Life-Sciences Inc., La Jolla Pharmaceutical Company, Genzyme Corporation, BioLine Rx Ltd.
The kidney/renal fibrosis treatment market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Kidney/Renal Fibrosis Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Kidney/Renal Fibrosis Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Kidney/Renal Fibrosis Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Kidney/Renal Fibrosis Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Kidney/Renal Fibrosis Treatment Market Size & Forecast, 2018-2028
4.5.1 Kidney/Renal Fibrosis Treatment Market Size and Y-o-Y Growth
4.5.2 Kidney/Renal Fibrosis Treatment Market Absolute $ Opportunity
Chapter 5 Global Kidney/Renal Fibrosis Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Kidney/Renal Fibrosis Treatment Market Size Forecast by Type
5.2.1 Angiotensin II Receptor Blockers (ARBs)
5.2.2 Angiotensin Converting Enzyme (ACE) Inhibitors
5.2.3 Pirfenidone
5.2.4 Renin Inhibitors
5.2.5 Vasopeptidase Inhibitors
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Kidney/Renal Fibrosis Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Kidney/Renal Fibrosis Treatment Market Size Forecast by Applications
6.2.1 Commercial/Private Hospitals
6.2.2 Public Health Hospitals
6.2.3 Clinics
6.2.4 Home Treatment
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Kidney/Renal Fibrosis Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Kidney/Renal Fibrosis Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Kidney/Renal Fibrosis Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Kidney/Renal Fibrosis Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Kidney/Renal Fibrosis Treatment Market Size Forecast by Type
9.6.1 Angiotensin II Receptor Blockers (ARBs)
9.6.2 Angiotensin Converting Enzyme (ACE) Inhibitors
9.6.3 Pirfenidone
9.6.4 Renin Inhibitors
9.6.5 Vasopeptidase Inhibitors
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Kidney/Renal Fibrosis Treatment Market Size Forecast by Applications
9.10.1 Commercial/Private Hospitals
9.10.2 Public Health Hospitals
9.10.3 Clinics
9.10.4 Home Treatment
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Kidney/Renal Fibrosis Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Kidney/Renal Fibrosis Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Kidney/Renal Fibrosis Treatment Market Size Forecast by Type
10.6.1 Angiotensin II Receptor Blockers (ARBs)
10.6.2 Angiotensin Converting Enzyme (ACE) Inhibitors
10.6.3 Pirfenidone
10.6.4 Renin Inhibitors
10.6.5 Vasopeptidase Inhibitors
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Kidney/Renal Fibrosis Treatment Market Size Forecast by Applications
10.10.1 Commercial/Private Hospitals
10.10.2 Public Health Hospitals
10.10.3 Clinics
10.10.4 Home Treatment
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Kidney/Renal Fibrosis Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Kidney/Renal Fibrosis Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Kidney/Renal Fibrosis Treatment Market Size Forecast by Type
11.6.1 Angiotensin II Receptor Blockers (ARBs)
11.6.2 Angiotensin Converting Enzyme (ACE) Inhibitors
11.6.3 Pirfenidone
11.6.4 Renin Inhibitors
11.6.5 Vasopeptidase Inhibitors
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Kidney/Renal Fibrosis Treatment Market Size Forecast by Applications
11.10.1 Commercial/Private Hospitals
11.10.2 Public Health Hospitals
11.10.3 Clinics
11.10.4 Home Treatment
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Kidney/Renal Fibrosis Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Kidney/Renal Fibrosis Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Kidney/Renal Fibrosis Treatment Market Size Forecast by Type
12.6.1 Angiotensin II Receptor Blockers (ARBs)
12.6.2 Angiotensin Converting Enzyme (ACE) Inhibitors
12.6.3 Pirfenidone
12.6.4 Renin Inhibitors
12.6.5 Vasopeptidase Inhibitors
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Kidney/Renal Fibrosis Treatment Market Size Forecast by Applications
12.10.1 Commercial/Private Hospitals
12.10.2 Public Health Hospitals
12.10.3 Clinics
12.10.4 Home Treatment
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Kidney/Renal Fibrosis Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Kidney/Renal Fibrosis Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Kidney/Renal Fibrosis Treatment Market Size Forecast by Type
13.6.1 Angiotensin II Receptor Blockers (ARBs)
13.6.2 Angiotensin Converting Enzyme (ACE) Inhibitors
13.6.3 Pirfenidone
13.6.4 Renin Inhibitors
13.6.5 Vasopeptidase Inhibitors
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Kidney/Renal Fibrosis Treatment Market Size Forecast by Applications
13.10.1 Commercial/Private Hospitals
13.10.2 Public Health Hospitals
13.10.3 Clinics
13.10.4 Home Treatment
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Kidney/Renal Fibrosis Treatment Market: Competitive Dashboard
14.2 Global Kidney/Renal Fibrosis Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Galectin Therapeutics
14.3.2 Merck & Co.
14.3.3 F. Hoffman-La Roche Ltd.
14.3.4 Pfizer Inc.
14.3.5 InterMune Inc.
14.3.6 ProMetic Life-Sciences Inc.
14.3.7 La Jolla Pharmaceutical Company
14.3.8 Genzyme Corporation
14.3.9 BioLine Rx Ltd
